🇺🇸 FDA
Patent

US 8802844

Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis

granted A61PA61P11/00A61P13/12

Quick answer

US patent 8802844 (Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis) held by Vertex Pharmaceuticals Incorporated expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P11/00, A61P13/12, A61P19/02, A61P19/08